Xiangkun (Shawn) Yang

Xiangkun (Shawn) Yang has a diverse work experience in the field of analytical chemistry and bioanalysis. Xiangkun (Shawn) is currently working at Prime Medicine, Inc. as a Senior Scientist II. In this role, they are responsible for developing analytical assays to support cell and gene therapy product development. Xiangkun (Shawn) collaborates with various teams to understand product quality and activity and guides analytical and process control strategies.

Prior to their current position, Xiangkun worked at Regeneron Pharmaceuticals, Inc. as a Scientist. Here, they led analytical chemistry activities in the developability assessment function and provided recommendations for lead candidate selection. Xiangkun (Shawn) also assessed potential clinical impacts through in vitro and in vivo studies.

Xiangkun also gained experience working at the FDA as an Orise Fellow. During this time, they focused on the analytical characterization of therapeutic proteins using novel methods. Their work contributed to the development of regulatory standards and FDA guidance for the industry.

Before joining the FDA, Xiangkun worked as a Graduate Research Assistant at The University of Georgia. Xiangkun (Shawn) developed and validated bioanalytical methods for the quantitation of protein post-translational modifications and studied the metabolism of specific compounds in neurons and astrocytes.

Additionally, Xiangkun had a summer internship at Amgen where they established an activity-based protein profiling platform for investigating xenobiotic metabolism. This platform helped identify enzymes involved in drug metabolism, providing valuable support for drug discovery and development programs.

Overall, Xiangkun's work experience demonstrates their expertise in analytical chemistry, bioanalysis, and product development in the pharmaceutical industry.

Xiangkun (Shawn) Yang completed their education with a Bachelor of Science (B.S.) in Pharmacy from Sichuan University, where they studied from 2007 to 2011. Following this, they pursued a Doctor of Philosophy (Ph.D.) in Pharmaceutical Analysis and Analytical Chemistry at The University of Georgia from 2013 to 2017.

In addition to their academic degrees, Xiangkun Yang also obtained certifications in Noncompartmental Data Analysis from Certara in July 2021, and a Regulatory Affairs Certificate from The University of Georgia in May 2017.